Free Trial

Aquestive Therapeutics (AQST) News Today

Aquestive Therapeutics logo
$2.72 -0.01 (-0.18%)
As of 11:06 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AQST Latest News

Aquestive Therapeutics, Inc. stock logo
Woodline Partners LP Reduces Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Woodline Partners LP trimmed its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 49.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 409,314 shares of the company's stock after selling 406,93
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by VR Adviser LLC
VR Adviser LLC trimmed its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 52.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,629,786 shares of the company's stock after sel
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of "Buy" by Analysts
Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twe
Aquestive Therapeutics, Inc. stock logo
Stonepine Capital Management LLC Acquires New Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Stonepine Capital Management LLC acquired a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 160,000
HC Wainwright Issues Pessimistic Outlook for AQST Earnings
Aquestive Therapeutics, Inc. stock logo
Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now expects that the company
Aquestive Therapeutics, Inc. stock logo
MPM Bioimpact LLC Has $5.74 Million Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
MPM Bioimpact LLC cut its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 10.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,611,833 shares of the company's stock after selling 184,917
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics (NASDAQ:AQST) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07).
Aquestive Therapeutics, Inc. stock logo
Raymond James Financial Inc. Acquires New Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Raymond James Financial Inc. purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 139,591 shares of the company's stock, valued at approximately $498,000. Ra
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by DAFNA Capital Management LLC
DAFNA Capital Management LLC lessened its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 78.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 127,000 shares of the company's stock after selling 462,561 shares during the period
Aquestive Therapeutics, Inc. stock logo
Stifel Financial Corp Buys 302,617 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Stifel Financial Corp lifted its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 315.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 398,561 shares of the company's stock after purchasing an additional 302,617 shares during the
Aquestive Therapeutics, Inc. stock logo
Invesco Ltd. Reduces Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Invesco Ltd. cut its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 93.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,944 shares of the company's stock after selling 738,635 shares during the quarter
Aquestive Therapeutics, Inc. stock logo
JPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
JPMorgan Chase & Co. cut its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 80.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,500 shares of the company's st
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics (AQST) Expected to Announce Earnings on Tuesday
Aquestive Therapeutics (NASDAQ:AQST) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-aquestive-therapeutics-inc-stock/)
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from Analysts
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been given a consensus recommendation of "Buy" by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating t
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Holdings Lowered by Blue Owl Capital Holdings LP
Blue Owl Capital Holdings LP lowered its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 26.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 900,000 shares of the company's stock
Aquestive Therapeutics, Inc. stock logo
Franklin Resources Inc. Reduces Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Franklin Resources Inc. decreased its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,134,796 shares of the company's stock af
Aquestive Therapeutics, Inc. stock logo
Raymond James Financial Inc. Invests $498,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Raymond James Financial Inc. purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 139,591 shares of the company's stock, valued
Aquestive Therapeutics, Inc. stock logo
What is HC Wainwright's Estimate for AQST Q1 Earnings?
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Aquestive Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics (NASDAQ:AQST) Earns Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Wednesday.
Aquestive Therapeutics (AQST) Gets a Buy from Lake Street
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Position Lowered by Everstar Asset Management LLC
Everstar Asset Management LLC trimmed its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 46.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 216,223 shares of the company's stock after se
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of "Buy" from Analysts
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has earned a consensus recommendation of "Buy" from the eight research firms that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned
Aquestive Therapeutics, Inc. stock logo
EntryPoint Capital LLC Acquires 112,210 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)
EntryPoint Capital LLC increased its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 475.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,797 shares of the company's stoc
Aquestive Therapeutics: Not For Me, But Attractive
Aquestive Therapeutics, Inc. stock logo
Analysts Offer Predictions for AQST FY2026 Earnings
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright issued their FY2026 earnings per share estimates for Aquestive Therapeutics in a research note issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.56)
Aquestive Therapeutics, Inc. stock logo
What is HC Wainwright's Forecast for AQST Q1 Earnings?
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects
Aquestive Therapeutics, Inc. stock logo
Aquestive Therapeutics (NASDAQ:AQST) Earns "Buy" Rating from HC Wainwright
HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Monday.
Get Aquestive Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.

AQST Media Mentions By Week

AQST Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AQST
News Sentiment

0.87

0.87

Average
Medical
News Sentiment

AQST News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AQST Articles
This Week

5

3

AQST Articles
Average Week

Get Aquestive Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AQST) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners